Nasdaq GlobeNewswire

Datameer Names New Award-Winning Marketing and Sales Executives

Del

Company Appoints Steve Dille as CMO and Laura Craig as VP of North American Sales

 

SAN FRANCISCO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Datameer, the leading big data preparation and exploration platform, today announced the appointment of Steve Dille as Chief Marketing Officer, reporting to CEO Christian Rodatus, and Laura Craig as Vice President of North American Sales, reporting to Chief Revenue Officer Jeff Gallagher. Recognized leaders in technology marketing and sales, Steve and Laura bring over 40 years of combined experience successfully penetrating and expanding markets, implementing new go-to-market strategies and accelerating business growth.

"Steve has demonstrated impressive expertise translating strategy and market intelligence into successful go-to-market plans," said Christian Rodatus, Datameer CEO. "His ability to execute for triple digit revenue percentage gains will be invaluable as we launch new partnerships and capabilities and accelerate business momentum. Laura joins the Datameer team from Teradata, where she continuously achieved double digit growth and received countless sales and leadership awards. Steve and Laura will be key to helping Datameer push further into our target verticals, expand our footprint and support impactful growth initiatives through 2018 and beyond."

Steve Dille - B2B Marketing Expert, Speaker and Columnist
A well-recognized leader, expert in enterprise data management, sought-after speaker and technology marketing columnist, Steve is a two-time public company CMO and 5-time VC-backed company CMO. He joins Datameer from SparkPost, where under his lead, the company doubled new logo acquisition and transformed into the largest cloud email provider, sending over 25% of the world's email. Before SparkPost, as CMO at MSCI, Steve drove 8-digit growth of the SaaS product, halted 50% customer attrition rate with a new channel distribution partnership and drove 100% growth in the hedge fund data and analytics business. Steve is responsible for building Datameer's global brand, shaping and amplifying strategic messages, and overseeing product, partner, demand generation and corporate marketing across all channels and geographies.

Laura Craig - Award-Winning Sales Leader
Laura joins Datameer after 17 years at Teradata, most recently as VP of Sales and a member of Teradata's Transformation leadership team. At Teradata, she achieved double-digit growth YOY with an annual quota as high as $65M, and received a myriad of awards including the Distinguished Pinnacle Award, President's Award, and more. Appointed to Teradata's Global Sales Council, Laura worked closely with product engineering and marketing, built strategic alliance partnerships and worked with leadership to develop strategy, offerings, value propositions and messaging. At Datameer, Laura leads the North America sales organization, driving growth initiatives and collaborating with customers and partners to help them effectively leverage Datameer for innovation and competitive advantage.

About Datameer
Datameer is changing the way companies do business by enabling them to get value and insights from their data at the speed of thought to make better, more trustworthy decisions. Leading global organizations, including Citibank, American Airlines, Telefonica, Comcast, National Instruments, and Vivint, use our secure and scalable enterprise-grade platform to streamline and simplify data integration and exploration so subject matter experts can leverage trusted data to cultivate innovation, creativity and efficiency for competitive advantage. Learn more at www.datameer.com.

Contact:
Samantha Leggat
samantha.leggat@datameer.com
415-802-2540



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Datameer via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Manufacturing Leadership Forum Will Highlight Enabling Industry 4.0 with Analytics25.9.2018 15:06Pressemelding

Upcoming Dates in Houston, Texas and Antwerp, Belgium PORTLAND, Ore., Sept. 25, 2018 (GLOBE NEWSWIRE) -- New dates for The Manufacturing Leadership Forum were announced today including Houston, Texas, US on October 9, 2018 at the Petroleum Club of Houston and on November 28, 2018 in Antwerp, Belgium at the Lindner WTC Hotel & City Lounge. The events are sponsored by Northwest Analytics, a leading provider of manufacturing intelligence and SPC software solutions for manufacturers. This premier manufacturing analytics educational event focuses on enabling Industry 4.0 programs with manufacturing analytics. The Forums will feature keynotes and case-study presentations from globally-recognized leaders in the application of manufacturing analytics. In its fourth year, The Manufacturing Leadership Forum will open with a keynote from analytics visionary, Dr. Lloyd Colegrove, Director of Data Services & Fundamental Problem Solving at The Dow Chemical Company. “The Manufacturing Leadership Foru

Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-10125.9.2018 14:00Pressemelding

Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 were presented yesterday in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer in Toronto. The oral presentation included further details on, and updates from, the dataset announced previously. CK-101 is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being evaluated in advanced non

SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test25.9.2018 14:00Pressemelding

Test supports international guidelines for treating antibiotic resistant STI SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not available for sale in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen or MG, along with genetic markers linked to antibiotic resistance. In recent years, Mgen prevalence has increased globally and developed high rates of resistance to the common antibiotic treatment, azithromycin. "This test is an exciting new development that will increase the precision of patient care for patients impacted by Mycoplasma genitalium - a common sexually transmitted infection with limited treatment options,” notes Dr Maria Trent, Professor of Pediatrics and Public Health at Johns Hopkins Medicine. The SpeeDx ResistancePlus MG test is in use in laboratories acr

Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults25.9.2018 13:00Pressemelding

First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulations Top-line immunogenicity and safety data expected in the first quarter of 2019 Phase 2 results will support meeting with the U.S. Food and Drug Administration (FDA) and Phase 3 clinical trial design GAITHERSBURG, Md., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate. “Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With top-line results expected in the first quarter of 2019, we plan to discuss these data with the FDA at an ‘End of Phase 2’ meeting and to agree on the appropriate Phase 3 clinical trial design to support licensure via accelerated approval. We continue to believe NanoFlu is a differen

CGAP Launches Photo and Video Contest Theme for 2018: Financial Inclusion in Africa25.9.2018 13:00Pressemelding

This year's CGAP contest is the first ever to accept short video entries WASHINGTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- The Consultative Group to Assist the Poor’s (CGAP) 13th annual photo contest, launched today, is seeking striking images on financial inclusion in Africa. For the first time, short video submissions on Africa also will be accepted. Entries may be submitted through December 14, 2018. Each contestant may submit up to 20 photos or videos to compete for the Grand Prize worth US$ 2,000. This year CGAP is looking for original and compelling photographs and short videos that tell the story of how financial services empower poor people and communities in Africa. The region is a center for financial innovation -- home to M-Pesa, the mobile money service launched a decade ago now replicated across markets worldwide; host to vibrant FinTech and e-commerce companies; and to a growing off-grid sector that leverages digital finance. Together these innovators contribute toward lifti

Kick-starting health in the workplace25.9.2018 10:00Pressemelding

Over 800 organizations step, bike, swim and yoga their way to better health and wellbeing as the May 2018 Virgin Pulse Global Challenge Concludes ZURICH, Switzerland, Sept. 25, 2018 (GLOBE NEWSWIRE) -- On August 30th more than 270,000 people, across 144 countries, completed Virgin Pulse’s 100-day Global Challenge, moving them towards a more active, healthy and productive lifestyle. With this achievement, Virgin Pulse, an international leader in employee health and wellbeing, once again proves it’s helping to improve employee lives for good. The company’s Global Challenge event encourages exercise, mindfulness and healthy habits at work, leading to a happier culture and reduced costs to the organization. “Through increased awareness, education and motivation, employees master long-term, sustainable habits allowing them to arrive at work feeling more engaged, productive and equipped for peak performance,” says David Osborne, Chief Executive Officer of Virgin Pulse. “The follow-on effects

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom